{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:54:39Z","timestamp":1788184479047,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MEXT KAKENHI","award":["JP21K15561"],"award-info":[{"award-number":["JP21K15561"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Lutetium-177 (<jats:sup>177<\/jats:sup>Lu) is a promising radionuclide for targeted cancer therapy due to its favorable theranostic properties. Transarterial lipiodol embolization is widely used for hepatocellular carcinoma (HCC), but the potential of <jats:sup>177<\/jats:sup>Lu emulsified into lipiodol (<jats:sup>177<\/jats:sup>Lu-lipiodol) remains underexplored. This study aimed to evaluate the partition coefficient, biodistribution, and antitumor efficacy of <jats:sup>177<\/jats:sup>Lu-lipiodol in a preclinical xenograft model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>After synthesizing <jats:sup>177<\/jats:sup>Lu-oxine from <jats:sup>177<\/jats:sup>Lu-chloride, the product was emulsified in lipiodol. Its radiochemical purity and partition coefficient were measured. F344 NJcl rnu\/nu rats (n\u2009=\u20095) bearing bilateral thigh tumors (HC-4 cells) were randomized to receive <jats:sup>177<\/jats:sup>Lu-lipiodol (2.8\u00a0MBq in 50 \u03bcL) or non-labeled lipiodol (50 \u03bcL) via surgical exposure and direct puncture of the right femoral artery. SPECT\/CT images were acquired over 14\u00a0days, and biodistribution was confirmed by gamma counting at day 28. Tumor volumes and body weights were monitored to assess treatment response and toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The <jats:sup>177<\/jats:sup>Lu-lipiodol emulsion was obtained with a high radiochemical purity (&gt;\u200999%). SPECT\/CT showed high tumor accumulation (34.0%\u2009\u00b1\u20094.4% immediately post-injection) that persisted up to day 28 (7.3%\u2009\u00b1\u20091.2% of injected dose). Tumor growth was significantly suppressed with a treated-to-untreated volume ratio of 0.45 at day 14 (p\u2009=\u20090.017) and 0.59 at day 21 (p\u2009=\u20090.001). While off-target uptake was limited, moderate splenic accumulation (26.6%\u2009\u00b1\u200917.5% ID) was noted. No marked body weight changes or gross organ abnormalities were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>\n              <jats:sup>177<\/jats:sup>Lu-lipiodol for HCC therapy demonstrated effective tumor targeting and growth suppression of HCC in a preclinical xenograft model.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11307-025-02016-1","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:26:50Z","timestamp":1749032810000},"page":"570-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of 177Lu-Labeled Lipiodol as a Targeted Radionuclide Therapy for Hepatocellular Carcinoma in a Preclinical Xenograft Model"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7977-0272","authenticated-orcid":false,"given":"Yumiko","family":"Kono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Shiojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Tanigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"5","key":"2016_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3892\/etm.2024.12514","volume":"27","author":"T Niu","year":"2024","unstructured":"Niu T, Fan M, Lin B, Gao F, Tan B, Du X (2024) Current clinical application of lutetium-177 in solid tumors (Review). Exp Ther Med 27(5):225. https:\/\/doi.org\/10.3892\/etm.2024.12514","journal-title":"Exp Ther Med"},{"issue":"8","key":"2016_CR2","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M et al (2016) PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med 57(8):1170\u20131176. https:\/\/doi.org\/10.2967\/jnumed.115.171397","journal-title":"J Nucl Med"},{"issue":"7","key":"2016_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2967\/jnumed.118.216820","volume":"60","author":"TW Barber","year":"2019","unstructured":"Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP (2019) Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med 60(7):955\u2013962. https:\/\/doi.org\/10.2967\/jnumed.118.216820","journal-title":"J Nucl Med"},{"issue":"12","key":"2016_CR4","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1093\/oncolo\/oyac216","volume":"27","author":"R AlSadi","year":"2022","unstructured":"AlSadi R, Bouhali O, Dewji S, Djekidel M (2022) 177Lu-PSMA therapy for metastatic castration-resistant prostate cancer: a mini-review of state-of-the-art. Oncologist 27(12):e957\u2013e966. https:\/\/doi.org\/10.1093\/oncolo\/oyac216","journal-title":"Oncologist"},{"issue":"2","key":"2016_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"issue":"15_sppl","key":"2016_CR6","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2021.39.15_suppl.4112","volume":"39","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL et al (2021) Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. JCO 39(15_sppl):4112\u20134112. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4112","journal-title":"JCO"},{"issue":"5","key":"2016_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164\u20131171. https:\/\/doi.org\/10.1053\/jhep.2002.33156","journal-title":"Hepatology"},{"issue":"1","key":"2016_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 64(1):106\u2013116. https:\/\/doi.org\/10.1002\/hep.28453","journal-title":"Hepatology"},{"issue":"2","key":"2016_CR9","first-page":"176","volume":"10","author":"WD Ensminger","year":"1983","unstructured":"Ensminger WD, Gyves JW (1983) Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10(2):176\u2013182","journal-title":"Semin Oncol"},{"issue":"1","key":"2016_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.1840100119","volume":"10","author":"T Kanematsu","year":"1989","unstructured":"Kanematsu T, Furuta T, Takenaka K et al (1989) A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 10(1):98\u2013102. https:\/\/doi.org\/10.1002\/hep.1840100119","journal-title":"Hepatology"},{"issue":"6","key":"2016_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2967\/jnumed.113.131367","volume":"55","author":"J Dumortier","year":"2014","unstructured":"Dumortier J, Decullier E, Hilleret MN et al (2014) Adjuvant intraarterial lipiodol or 131I-lipiodol after curative treatment of hepatocellular carcinoma: a prospective randomized trial. J Nucl Med 55(6):877\u2013883. https:\/\/doi.org\/10.2967\/jnumed.113.131367","journal-title":"J Nucl Med"},{"issue":"2","key":"2016_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00259-003-1363-2","volume":"31","author":"F Sundram","year":"2004","unstructured":"Sundram F, Chau TCM, Onkhuudai P, Bernal P, Padhy AK (2004) Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 31(2):250\u2013257. https:\/\/doi.org\/10.1007\/s00259-003-1363-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2016_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1055\/s-0043-1764306","volume":"22","author":"N Kumar","year":"2023","unstructured":"Kumar N, Gupta P, Shamim SA et al (2023) 188 Re-N-DEDC lipiodol for treatment of hepatocellular carcinoma (HCC)\u2014a clinical and prospective study to assess in-vivo distribution in patients and clinical feasibility of therapy. World J Nucl Med 22(2):114\u2013123. https:\/\/doi.org\/10.1055\/s-0043-1764306","journal-title":"World J Nucl Med"},{"issue":"5","key":"2016_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1089\/cbr.2010.0792","volume":"25","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Das T, Chakraborty S et al (2010) Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study. Cancer Biother Radiopharm 25(5):539\u2013543. https:\/\/doi.org\/10.1089\/cbr.2010.0792","journal-title":"Cancer Biother Radiopharm"},{"issue":"11","key":"2016_CR15","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1158\/1535-7163.MCT-14-0151","volume":"13","author":"Y Kono","year":"2014","unstructured":"Kono Y, Utsunomiya K, Kanno S, Tanigawa N (2014) Longitudinal time-dependent effects of irradiation on multidrug resistance in a non-small lung cancer cell line. Mol Cancer Ther 13(11):2706\u20132712. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0151","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2016_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0969-8043(03)00064-2","volume":"58","author":"J Yu","year":"2003","unstructured":"Yu J, H\u00e4feli UO, Sands M, Dong Y (2003) 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer. Appl Radiat Isot 58(5):567\u2013573. https:\/\/doi.org\/10.1016\/S0969-8043(03)00064-2","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"2016_CR17","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H et al (2019) Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 71(6):1164\u20131174. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.006","journal-title":"J Hepatol"},{"issue":"12","key":"2016_CR18","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/cancers13122912","volume":"13","author":"CH Rim","year":"2021","unstructured":"Rim CH, Park S, Shin IS, Yoon WS (2021) Is the concurrent use of sorafenib and external radiotherapy feasible for advanced hepatocellular carcinoma? A meta-analysis. Cancers (Basel) 13(12):2912. https:\/\/doi.org\/10.3390\/cancers13122912","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2016_CR19","first-page":"1782","volume":"35","author":"JL Raoul","year":"1994","unstructured":"Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M (1994) Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versusmedical support. J Nucl Med 35(11):1782\u20131787","journal-title":"J Nucl Med"},{"key":"2016_CR20","doi-asserted-by":"publisher","first-page":"278306","DOI":"10.1155\/2012\/278306","volume":"2012","author":"N Lepareur","year":"2012","unstructured":"Lepareur N, Ardisson V, Noiret N, Garin E (2012) 188Re-SSS\/lipiodol: development of a potential treatment for HCC from bench to bedside. Int J Mol Imaging 2012:278306. https:\/\/doi.org\/10.1155\/2012\/278306","journal-title":"Int J Mol Imaging"},{"key":"2016_CR21","doi-asserted-by":"publisher","unstructured":"Lepareur N, Lac\u0153uille F, Bouvry C et al (2019) Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives. Front Med 6.\u00a0https:\/\/doi.org\/10.3389\/fmed.2019.00132","DOI":"10.3389\/fmed.2019.00132"},{"issue":"7","key":"2016_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4236\/jct.2016.77054","volume":"7","author":"F Schulz","year":"2016","unstructured":"Schulz F, Friebe M (2016) SIRT and its unresolved problems\u2014is imaging the solution? Rev J Cancer Ther 7(7):505\u2013518. https:\/\/doi.org\/10.4236\/jct.2016.77054","journal-title":"Rev J Cancer Ther"},{"issue":"1","key":"2016_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41181-023-00205-3","volume":"8","author":"A Josefsson","year":"2023","unstructured":"Josefsson A, Cortez AG, Rajkumar H et al (2023) Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the \u03b1-particle-emitting transarterial radioembolization (\u03b1TARE) agent [225Ac]Ac-DOTA-TDA-Lipiodol\u00ae against hepatic tumors. EJNMMI Radiopharm Chem 8(1):19. https:\/\/doi.org\/10.1186\/s41181-023-00205-3","journal-title":"EJNMMI Radiopharm Chem"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02016-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02016-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02016-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T07:02:15Z","timestamp":1756882935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02016-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02016-1","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This animal study was approved by the Institutional Animal Care and Use Committee (IACUC) of Kansai Medical University (Approval Number: 24\u2013057).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}